Bayesian network inference modeling identifies TRIB1 as a novel regulator of cell-cycle progression and survival in cancer cells

Rina Gendelman, Heming Xing, Olga K. Mirzoeva, Preeti Sarde, Christina Curtis, Heidi Feiler, Paul McDonagh, Joe Gray, Iya Khalil, W. Michael Korn

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Molecular networks governing responses to targeted therapies in cancer cells are complex dynamic systems that demonstrate nonintuitive behaviors. We applied a novel computational strategy to infer probabilistic causal relationships between network components based on gene expression. We constructed a model comprised of an ensemble of networks using multidimensional data from cell line models of cell-cycle arrest caused by inhibition of MEK1/2. Through simulation of a reverse-engineered Bayesian network model, we generated predictions of G1-S transition. The model identified known components of the cell-cycle machinery, such as CCND1, CCNE2, and CDC25A, as well as revealed novel regulators of G1-S transition, IER2, TRIB1, TRIM27. Experimental validation of model predictions confirmed 10 of 12 predicted genes to have a role in G1-S progression. Further analysis showed that TRIB1 regulated the cyclin D1 promoter via NFκB and AP-1 sites and sensitized cells to TRAIL-induced apoptosis. In clinical specimens of breast cancer, TRIB1 levels correlated with expression of NFκB and its target genes (IL8, CSF2), and TRIB1 copy number and expression were predictive of clinical outcome. Together, our results establish a critical role of TRIB1 in cell cycle and survival that is mediated via the modulation of NFκB signaling.

Original languageEnglish (US)
Pages (from-to)1575-1585
Number of pages11
JournalCancer Research
Volume77
Issue number7
DOIs
StatePublished - 2017

Fingerprint

Cell Survival
Cell Cycle
Cyclin D1
Transcription Factor AP-1
Cell Cycle Checkpoints
Interleukin-8
Genes
Neoplasms
Theoretical Models
Apoptosis
Breast Neoplasms
Gene Expression
Cell Line
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Bayesian network inference modeling identifies TRIB1 as a novel regulator of cell-cycle progression and survival in cancer cells. / Gendelman, Rina; Xing, Heming; Mirzoeva, Olga K.; Sarde, Preeti; Curtis, Christina; Feiler, Heidi; McDonagh, Paul; Gray, Joe; Khalil, Iya; Korn, W. Michael.

In: Cancer Research, Vol. 77, No. 7, 2017, p. 1575-1585.

Research output: Contribution to journalArticle

Gendelman, Rina ; Xing, Heming ; Mirzoeva, Olga K. ; Sarde, Preeti ; Curtis, Christina ; Feiler, Heidi ; McDonagh, Paul ; Gray, Joe ; Khalil, Iya ; Korn, W. Michael. / Bayesian network inference modeling identifies TRIB1 as a novel regulator of cell-cycle progression and survival in cancer cells. In: Cancer Research. 2017 ; Vol. 77, No. 7. pp. 1575-1585.
@article{d989ef31273e46d1ae6db54801ce47e6,
title = "Bayesian network inference modeling identifies TRIB1 as a novel regulator of cell-cycle progression and survival in cancer cells",
abstract = "Molecular networks governing responses to targeted therapies in cancer cells are complex dynamic systems that demonstrate nonintuitive behaviors. We applied a novel computational strategy to infer probabilistic causal relationships between network components based on gene expression. We constructed a model comprised of an ensemble of networks using multidimensional data from cell line models of cell-cycle arrest caused by inhibition of MEK1/2. Through simulation of a reverse-engineered Bayesian network model, we generated predictions of G1-S transition. The model identified known components of the cell-cycle machinery, such as CCND1, CCNE2, and CDC25A, as well as revealed novel regulators of G1-S transition, IER2, TRIB1, TRIM27. Experimental validation of model predictions confirmed 10 of 12 predicted genes to have a role in G1-S progression. Further analysis showed that TRIB1 regulated the cyclin D1 promoter via NFκB and AP-1 sites and sensitized cells to TRAIL-induced apoptosis. In clinical specimens of breast cancer, TRIB1 levels correlated with expression of NFκB and its target genes (IL8, CSF2), and TRIB1 copy number and expression were predictive of clinical outcome. Together, our results establish a critical role of TRIB1 in cell cycle and survival that is mediated via the modulation of NFκB signaling.",
author = "Rina Gendelman and Heming Xing and Mirzoeva, {Olga K.} and Preeti Sarde and Christina Curtis and Heidi Feiler and Paul McDonagh and Joe Gray and Iya Khalil and Korn, {W. Michael}",
year = "2017",
doi = "10.1158/0008-5472.CAN-16-0512",
language = "English (US)",
volume = "77",
pages = "1575--1585",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "7",

}

TY - JOUR

T1 - Bayesian network inference modeling identifies TRIB1 as a novel regulator of cell-cycle progression and survival in cancer cells

AU - Gendelman, Rina

AU - Xing, Heming

AU - Mirzoeva, Olga K.

AU - Sarde, Preeti

AU - Curtis, Christina

AU - Feiler, Heidi

AU - McDonagh, Paul

AU - Gray, Joe

AU - Khalil, Iya

AU - Korn, W. Michael

PY - 2017

Y1 - 2017

N2 - Molecular networks governing responses to targeted therapies in cancer cells are complex dynamic systems that demonstrate nonintuitive behaviors. We applied a novel computational strategy to infer probabilistic causal relationships between network components based on gene expression. We constructed a model comprised of an ensemble of networks using multidimensional data from cell line models of cell-cycle arrest caused by inhibition of MEK1/2. Through simulation of a reverse-engineered Bayesian network model, we generated predictions of G1-S transition. The model identified known components of the cell-cycle machinery, such as CCND1, CCNE2, and CDC25A, as well as revealed novel regulators of G1-S transition, IER2, TRIB1, TRIM27. Experimental validation of model predictions confirmed 10 of 12 predicted genes to have a role in G1-S progression. Further analysis showed that TRIB1 regulated the cyclin D1 promoter via NFκB and AP-1 sites and sensitized cells to TRAIL-induced apoptosis. In clinical specimens of breast cancer, TRIB1 levels correlated with expression of NFκB and its target genes (IL8, CSF2), and TRIB1 copy number and expression were predictive of clinical outcome. Together, our results establish a critical role of TRIB1 in cell cycle and survival that is mediated via the modulation of NFκB signaling.

AB - Molecular networks governing responses to targeted therapies in cancer cells are complex dynamic systems that demonstrate nonintuitive behaviors. We applied a novel computational strategy to infer probabilistic causal relationships between network components based on gene expression. We constructed a model comprised of an ensemble of networks using multidimensional data from cell line models of cell-cycle arrest caused by inhibition of MEK1/2. Through simulation of a reverse-engineered Bayesian network model, we generated predictions of G1-S transition. The model identified known components of the cell-cycle machinery, such as CCND1, CCNE2, and CDC25A, as well as revealed novel regulators of G1-S transition, IER2, TRIB1, TRIM27. Experimental validation of model predictions confirmed 10 of 12 predicted genes to have a role in G1-S progression. Further analysis showed that TRIB1 regulated the cyclin D1 promoter via NFκB and AP-1 sites and sensitized cells to TRAIL-induced apoptosis. In clinical specimens of breast cancer, TRIB1 levels correlated with expression of NFκB and its target genes (IL8, CSF2), and TRIB1 copy number and expression were predictive of clinical outcome. Together, our results establish a critical role of TRIB1 in cell cycle and survival that is mediated via the modulation of NFκB signaling.

UR - http://www.scopus.com/inward/record.url?scp=85017318736&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017318736&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-16-0512

DO - 10.1158/0008-5472.CAN-16-0512

M3 - Article

C2 - 28087598

AN - SCOPUS:85017318736

VL - 77

SP - 1575

EP - 1585

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 7

ER -